Atlas Trials

ADAM17 Inhibitor/ Rituximab After Auto HCT for DLBCL

Clinical trial NCT02141451 · COMPLETED

Trial details

NCT number
NCT02141451
Sponsor
Masonic Cancer Center, University of Minnesota
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Diffuse Large B Cell Non-Hodgkin Lymphoma
Start date
2014-05-01
Primary completion
2019-01-23
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.